User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Bortezomib-induced histiocytoid Sweet syndrome

Primary tabs

Murase, Jenny E. Théate, Ivan [UCL] Wu, Jashin J. Cole, Gary W. Barr, Ronald J. Dyson, Senait W.

Bortezomib, a proteasome inhibitor approved for the treatment of multiple myeloma, has been reported to be associated with Sweet syndrome. However, careful review of the histopathology of the first reported case and our case revealed similar histologic and immunohistochemical findings (a mononuclear dermal infiltrate) and not the usual neutrophilic infiltrate of Sweet syndrome. We suggest that the dermatitis induced by bortezomib is best classified as "histiocytoid Sweet syndrome." (J Am Acad Dermatol 2009;60:496-7.)

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès restreint
Publication date 2009
Language Anglais
Journal information "Journal of the American academy of dermatology" - Vol. 60, no. 3, p. 496-497 (2009)
Peer reviewed yes
Publisher Mosby-elsevier (New York)
issn 0190-9622
e-issn 1097-6787
Publication status Publié
Affiliations UCL - Cliniques universitaires Saint-Luc
UCL
Links
Bibliographic reference Murase, Jenny E. ; Théate, Ivan ; Wu, Jashin J. ; Cole, Gary W. ; Barr, Ronald J. ; et. al. Bortezomib-induced histiocytoid Sweet syndrome. In: Journal of the American academy of dermatology, Vol. 60, no. 3, p. 496-497 (2009)
Permanent URL http://hdl.handle.net/2078.1/36168